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Abstract
In recent years, the neglected diseases drug discovery community has elected phenotypic
screening as the key approach for the identification of novel hit compounds. However, when
this approach is applied, important questions related to the mode of action for these com-
pounds remain unanswered. One of such questions is related to the rate of action, a useful
piece of information when facing the challenge of prioritising the most promising hit com-
pounds. In the present work, compounds of the “Leishmania donovani box” were evaluated
using a rate of action assay adapted from a replicative intracellular high content assay
recently developed. The potency of each compound was determined every 24 hours up to
96 hours, and standard drugs amphotericin B and miltefosine were used as references to
group these compounds according to their rate of action. Independently of this biological
assessment, compounds were also clustered according to their minimal chemical scaffold.
Comparison of the results showed a complete correlation between the chemical scaffold
and the biological group for the vast majority of compounds, demonstrating how the assay
was able to bring information on the rate of action for each chemical series, a property
directly linked to the mode of action. Overall, the assay here described permitted us to evalu-
ate the rate of action of the “Leishmania donovani box” using two of the currently available
drugs as references and, also, to propose a number of fast-acting chemical scaffolds pres-
ent in the box as starting points for future drug discovery projects to the wider scientific com-
munity. The results here presented validate the use of this assay for the determination of the
rate of action early in the discovery process, to assist in the prioritisation of hit compounds.
Author summary
Visceral leishmaniasis is a parasitic disease, caused by Leishmania donovani and Leish-
mania infantum species, found in Asia, South America, East Africa and Southern Europe.
Currently available treatments present either serious side effects or high prices and, there-
fore, the identification of a new generation of antileishmanial drugs is clearly an unmet
medical need. In order to find new and safer drugs, pharmaceutical companies and
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research institutes have engaged in screening of large compound collections on cell-based
systems. These assays are more likely to predict the in vivo potency of the hits identified
compared to assays based on the inhibition of a specific target, but do not provide any
information regarding one of the most important parameters, together with PK/PD pro-
file, used to predict the effect of a drug as it is the mode of action. In addition, most of the
available assays rely on a single endpoint determination of compound potency and, there-
fore, do not evaluate rate of action, a property linked to the mode of action. Although
there is only limited knowledge on the PK/PD profile for current antileishmanial drugs
amphotericin B and miltefosine, the observation that in vitro fast-acting amphotericin B
requires shorter treatment regimen than in vitro slow-acting drug miltefosine seems to
suggest that this property could be very useful for progressing the most promising hit
compounds to more advanced stages of the drug discovery process. In fact, progression of
fast-acting compounds over slow-acting ones is the current strategy at the Kinetoplastid
DPU. For these reasons, we present here the application of a rate of action assay to a
promising compound set displaying potencies against the intracellular Leishmania dono-
vani parasite (”Leishmania donovani box”) in the micromolar to sub-micromolar range as
well as its validation for use in the hit prioritisation within drug discovery.
Introduction
Leishmania parasites are causative agents of different pathologies, ranging from self-curing but
disfiguring cutaneous leishmaniasis (CL) to visceral leishmaniasis (VL), mainly caused by L.
donovani species in humans and potentially lethal if untreated. The few treatments available
for VL, including amphotericin B (AB) and miltefosine (MF), are all characterized by impor-
tant drawbacks that underline the urgent need for new drugs [1]. For example, amphotericin B
showed successful cure rates after a single-dose administration [2]. However, it requires intra-
venous administration, patient hospitalization and unbroken cold chain that, together with the
high cost of the liposomal formulation, make it far from ideal for usage in endemic countries
[3]. Miltefosine, the only oral drug available to treat visceral leishmaniasis, is associated to tera-
togenicity and requires a long treatment course of at least 28 days, which represents a huge
obstacle to patient’s compliance [4].
For the last 25 years, drug discovery focused primarily on target-based approaches [5], that
rely on the ability of a drug to exert its effect through inhibition or interference with one or
more essential targets or pathways. These approaches always require an important initial effort
for the identification of the right targets, as their success is dependent on target essentiality
and druggability [6]. They are even more challenging for the kinetoplastids area due to the
small number of drug targets fully validated in the field [7,8], and also to the lack of knowledge
about mode of action for currently available drugs, which potency seems to reflect the inhibi-
tion of multiple targets or pathways [9].
For all these reasons, over the last few years, drug discovery against kinetoplastid parasites
has started to consider phenotypic screening [10,11], where compounds are tested directly on
a cell-based system and compound potency is evaluated on the basis of the insurgence of a
phenotype, which is usually death or reduced growth of the organism. One of the major limita-
tions of phenotypic screenings is the lack of information on the molecular target or mode of
action for the hits identified [12]. This gap also includes information on the rate of action,
defined as the time needed to reach maximum effect under the same in vitro experimental con-
ditions. This property can be inferred in many cases from the mode of action of promising
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hits, if known, or has to be specifically addressed otherwise. In fact, besides the filters tradition-
ally applied to compound prioritisation in the drug discovery process (mainly physico-chemi-
cal properties and toxicity), knowledge of their rate of action would provide an exceptional
piece of additional information. Recently, R&D efforts against other protozoan parasites like
P. falciparum, T. brucei and T. cruzi have addressed the question of determining the rate of
action of hit compounds to aid the selection of the most promising ones [13–17].
As part of the academia-industry partnership approach to defeat neglected tropical diseases,
GSK has very recently conducted a high throughput screening campaign with ca. 1.8 million
compounds belonging to the GSK compound collection against the three kinetoplastid para-
sites Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei, assembling three
boxes of an average of 200 hit compounds each, active against these parasites [18]. Also, we
have recently developed a high content L. donovani replicative intra-macrophage in vitro sys-
tem that appears to be a promising translational infection model [19]. In the present work, we
have further developed this assay to investigate its potential for the evaluation of compound
rate of action, and analysed in depth the use of this property in the prioritization of hit com-
pounds for early drug discovery programmes. To fully exploit the potential of the “L. donovani
box” recently published [18], in the present work, we determined the potency of these com-
pounds in the replicative intra-macrophage assay recently described [19], assessing the
potency of each compound every 24 hours up to 96 hours. This screening allowed us to obtain
time-to-kill information for each compound, to compare this information with amphotericin
B and miltefosine, and to group them into three different categories according to rate of action.
We also clustered the compounds according to their chemical structure and matched the
results from the two exercises, demonstrating how this assay can be applied to the hit progres-
sion cascade in drug discovery.
Materials and methods
Cell lines
The human biological samples were sourced ethically following GSK-HBSM guideline and
policies, their research use was in accord with the terms of the informed consents. THP-1 cells
(human monocytic leukemia) were made available by GSK-Biological Reagents and Assay
Development Department (GSK-BRAD, Stevenage, UK) and were maintained in RPMI media
(Life-Technologies) supplemented with 1.25 mM Pyruvate (Life-Technologies), 2.5 mM Gluta-
mine (Life-Technologies), 25 mM HEPES (Life-Technologies) and 10% heat inactivated FBS
(Gibco).
The Leishmania donovani strain (MHOM/SD/62/1S-CL2D, LdBOB) [20] expressing green
fluorescent protein (GFP) was kindly provided by Manu de Rycker (University of Dundee)
[21]. Axenic amastigotes were grown at 37˚C, 5% CO2 in media containing 15 mM KCl (Invi-
trogen™), 10 mM K2HPO4 (Merck), 136 mM KH2PO4 (Merck), 0.5 mM MgSO4 (Sigma-
Aldrich), 24 mM NaHCO3 (Invitrogen™), 25 mM Glucose (Sigma-Aldrich), 1mM L-Gluta-
mine (Invitrogen™), 1xRPMI Vitamin Solution (Sigma-Aldrich), 10 μM Folic Acid (Sigma-
Aldrich), 100 μM Adenosine (Sigma-Aldrich), 5 mg/L Hemin (Sigma-Aldrich), 1xRPMI
Amino Acid solution (Sigma-Aldrich), 25 mM MES, 0.0004% Phenol Red and 20% Heat Inac-
tivated FBS (Gibco) in Milli-Q water (pH = 5,5 at 37˚C). The selection antibody Lexsy NTC
(Nourseothricin, Jena Bioscience) was regularly added to amastigote cultures [21].
In vitro intra-macrophage L. donovani assay
The L. donovani intra-macrophage assay was adapted from previously described protocols [18,
19, 21], with the exception that four copies of compound plates were prepared to allow fixing
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and staining at different time points (24, 48, 72 and 96 hours). THP-1 cells were differentiated
in 225 cm3 flasks (6x105 cells/mL, 80 ml) with 30 nM of phorbol 12-myristate 13-acetate
(PMA, Sigma-Aldrich). After 24 h incubation, the media containing PMA was removed, wash-
ing twice with complete growth media. Differentiated THP-1 cells were infected with a suspen-
sion of axenic amastigotes in complete THP-1 growth media without PMA (6x106 parasites/
mL, 80ml) for 24 hours. The media was subsequently removed and the monolayer washed
with PBS. Cells were harvested with a solution of 0.25% (w/v) trypsin/EDTA in PBS, diluted to
1.6x105 cells/mL in assay media containing RPMI media supplemented with 2% Heat Inacti-
vated Horse Serum (Gibco), 25 mM NaHCO3 (Invitrogen™) and 30 nM PMA and dispensed
in assay plates with a Multidrop Combi dispenser (Thermo Scientific). Uninfected differenti-
ated THP-1 were treated following the same protocol and dispensed in each assay plate as
highest compound response control. Assay plates were incubated at 37˚C, 5% CO2 for 24, 48,
72 or 96 hours and then fixed with 4% formaldehyde for 30 min at room temperature (50 μl of
8% (v/v) formaldehyde solution (Sigma-Aldrich) in PBS/each well). Cells were then washed
twice with 100 μL PBS using an EL406 multi well platewasher (BioTek), stained with 30 μl of a
solution of DAPI (10μg/mL) and Triton X-100 (0.1% v/v) in PBS for 30 min at room tempera-
ture and washed twice with 50 μL PBS. Finally, 50 μL of PBS were added to each well, plates
were sealed and stored at 4˚C until analysis.
Four images per each well were acquired with a High-Content Screening System (Opera
QEHS, Perkin Elmer) using a 20x air objective. Two sequential images were taken exciting at
405 nm (DAPI) and 488 nm (GFP). Macrophages were identified with DAPI staining while
amastigotes were detected using the GFP signal. The images were analyzed with an image anal-
ysis algorithm developed on Acapella1 High Content Imaging and Analysis Software (Perki-
nElmer). THP-1 cell count (MAC), average number of amastigotes per macrophage (AM/
MAC) and percentage of infected cells (INF) were calculated for each well.
Test compounds and assay plates
Test compounds were made available by the GSK collection of compounds. Chemical struc-
tures and more information on all compounds tested in these studies are available at reference
18 as TCMDC IDs (Tres Cantos Medicine Discovery Center Identifiers). Amphotericin B
(AB) and miltefosine (MF) were purchased from Sigma Aldrich.
Of the total 192 compounds of the “L. donovani box”, 176 compounds were assayed due to
unavailability of 16 compounds at the time the work was carried out. Pre-dispensed 384-wells
assay plates (Greiner μclear black) were prepared by adding 250 nL of compounds dissolved in
100% DMSO to each well by using an Echo1 liquid handler (Labcyte Inc.). Eleven-point one
in three dilution curves were generated from a top concentration of 50 μM. Plates were stored
at -20˚C and allowed to equilibrate at room temperature before use.
Data analysis
Data were normalized to percentage biological response following the equation:
%Response ¼
jRCtrl1   Rxj
jRCtrl1   RCtrl2j
 100
where Rx is the assay response measured for each compound X, Rctrl1 the lowest response
achieved in absence of any test compound (negative control) and Rctrl2 the highest response
represented by non-infected cells (positive control). Control wells were included in each assay
plate and Rctrl1 and Rctrl2 were calculated as the average of the replicates.
Rate of action of “Leish box” hits
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0005629 May 25, 2017 4 / 16
Activities were expressed as pEC50 (pEC50 = -log EC50 (M)). The pEC50 values at each
time point for each compound were obtained using the ActivityBase XE nonlinear regression
function in the full curve analysis bundle to fit the 4-parameter logistic equation.
Analysis of pEC50 values
The pEC50 values of the compounds of the “L. donovani box” at each time point (24, 48, 72
and 96 hours) were calculated as described above using two outputs, AM/MAC and INF cells,
and the mean of two independent experiments was used for the analysis. The two outputs
were analyzed independently.
Only compounds showing pEC505 at 96h, corresponding to in vitro activity values in the
single-digit micromolar range or below (EC5010uM), were included in the analysis. Also,
compounds showing poor fitting curves or low maximum asymptote (<60%) were excluded
from the analysis. The list of remaining compounds was refined by applying the same filters
applied for the assembly of the “L. donovani box” [18]: Selectivity Index (SI) at 96h versus
THP-1 cells as primary toxicity determination (SI >5, pEC50AM/MAC/INF—pEC50MAC >0.7)
and versus HepG2 cells as secondary toxicity determination (SI >10, pEC50AM/MAC/INF—
pEC50HepG2 >1). For those compounds fulfilling the requirements described, the difference in
pEC50s between 96h and 24h (Δ96h-24h) and between 96h and 48h (Δ96h-48h) were calculated
and compared to the same parameters obtained for AB and MF. According to their Δ96h-24h
and Δ96h-48h values, each compound was assigned to one of the following “rate of action
groups”: group 1 for compounds faster or similar to AB, group 2 for compounds faster or simi-
lar to MF but slower than AB, and group 3 for compounds slower than both AB and MF.
Chemical clustering
The chemical structures of the high-quality compounds identified after application of potency
and selectivity filters to initial hits were individually analysed and used to chemically cluster
the compounds. A chemical scaffold was considered a cluster when it was present in at least
three molecules of the compound set.
Comparison between “rate of action” groups and chemical clusters
The compounds included in each chemical cluster described above were analyzed in terms of
“rate of action” group from the biological clustering exercise. The expected outcome was that
compounds belonging to a given chemical cluster should also be found in the same “rate of
action” group.
Results
Assay characterization
The mean pEC50 values (pEC50 = -log EC50 (M)) at each time point are shown in the supple-
mentary material (S1 Table for AM/MAC output and S2 Table for INF output). The assay
proved to be robust, with good to excellent Z prime values (S3 Table). The assay was also
highly reproducible, showing R2 values> 0.9 when comparing the two copies for the two out-
puts used, AM/MAC and INF, as shown in Fig 1.
Table 1 shows pEC50 values as well as pEC50 differences obtained for standard drugs
amphotericin B and miltefosine at each time point. pEC50 values obtained at 96h for both
drugs were comparable to previously reported data in horse serum and foetal bovine serum
[19, 21]. Amphotericin B reached its maximum effect in both outputs between 24 and 48
hours, while miltefosine reached its maximum effect clearly later than 48 hours.
Rate of action of “Leish box” hits
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Compound selection for clustering and analysis
The selection of the most promising compounds amongst the initial 176 hits tested was done
by application of a number of filters, including potency (pEC50>5), number of valid data
points in the kinetic, THP-1 selectivity (SI>5), and HepG2 selectivity (SI>10). Two final com-
pound sets, containing 88 and 73 high-value hits for the AM/MAC and INF outputs respec-
tively, were obtained (S4 and S5 Tables) and subjected to chemical clustering and biological
“rate of action” analysis.
Analysis of AM/MAC output
The 88 selected compounds were divided into 3 groups according to their Δ96h-24h and Δ96h-48h
values using as reference those values obtained for amphotericin B (0.29 and 0.05 respectively)
and miltefosine (0.98 and 0.23 respectively). Group 1 included those compounds faster, similar
or slightly slower than AB showing a Δ96h-24h<0.7. Group 2 was defined as those compounds
showing Δ96h-24h>0.7 and Δ96h-48h<0.5, being faster, similar, or slightly slower than MF but
clearly slower than AB. Finally, group 3, pooling compounds clearly slower than both AB and
MF, was defined as hits showing Δ96h-24h>0.7 and Δ96h-48h>0.5. Applying these filters, the 88
compounds were grouped as shown in S6 Table: 64 compounds in group 1, 17 compounds in
group 2 and 7 compounds in group 3.
Fig 1. Comparison of the pEC50 values obtained at 96 hours for the two assay runs using the AM/MAC output (left) and the INF output (right).
The R2 value calculated is shown at the top of each representation.
https://doi.org/10.1371/journal.pntd.0005629.g001
Table 1. pEC50 values of standard drugs amphotericin B (AB) and miltefosine (MF) at each time point calculated using the AM/MAC and INF out-
puts. pEC50 = -log EC50 (M). Values are expressed as mean value of two independent test runs. R2 values obtained for all curves studied were >0.85.
AM/MAC pEC5024h pEC5048h pEC5072h pEC5096h Δ96h-24h Δ96h-48h
AB 6.87 7.11 7.27 7.16 0.29 0.05
MF 5.31 6.05 6.22 6.28 0.98 0.23
INF pEC5024h pEC5048h pEC5072h pEC5096h Δ96h-24h Δ96h-48h
AB 6.82 6.98 7.06 7.02 0.20 0.04
MF 5.16 5.68 6.19 6.20 1.04 0.52
https://doi.org/10.1371/journal.pntd.0005629.t001
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In parallel, the same 88 compounds were clustered according to the presence of a minimum
common chemical scaffold. A set of seven clusters with at least 3 members totalling 35 com-
pounds was obtained. The remaining 53 hits were either singletons or belonged to a cluster
with less than 3 members. The chemical clusters obtained are shown in Table 2 and Fig 2.
Analysis of INF output
The 73 selected compounds were divided into 3 groups according to their Δ96h-24h and Δ96h-48h
values using as reference those values obtained for amphotericin B (0.20 and 0.04 respectively)
and miltefosine (1.04 and 0.52 respectively). In a similar way to the AM/MAC output, group 1
was defined as those compounds with Δ96h-24h<0.7. Group 2 was defined as those compounds
showing Δ96h-24h>0.7 and Δ96h-48h<0.7. Group 3 was defined as hits showing Δ96h-24h>0.7 and
Δ96h-48h>0.7. Applying these filters, we were able to group the compounds as follows: 49 com-
pounds in group 1, 13 compounds in group 2 and 11 compounds in group 3 (S7 Table).
In parallel, the same 73 compounds were clustered according to the presence of a minimum
common chemical scaffold. A set of seven clusters with at least 3 members comprising 34 com-
pounds were obtained. The remaining 39 compounds were either singletons or belonged to a
cluster with less than 3 members. Results can be found in Table 3 and Fig 2.
Comparison AM/MAC / INF outputs
The comparison of the results obtained for the 88 compounds selected using the AM/MAC
output and the corresponding 73 compounds using the INF output was carried out in order to
investigate the correlation between the two outputs. Full data set for the two outputs, including
information on the group and comments, was available for 68 compounds and the results
obtained are shown in S8 Table. Correlation was considered “excellent” for those compounds
included clearly in the same group (group 1, 2 or 3) independent of the output applied, “good”
for those compounds showing agreement between the two outputs although not presenting a
clear decision for one of the outputs and “poor” for those compounds included clearly in dif-
ferent groups for the two outputs. According to this rule, 59 compounds (87%) showed “excel-
lent” correlation, 6 compounds (9%) presented “good” correlation and 3 compounds (4%)
were included in the “poor” correlation group.
Table 2. Chemical clusters (Cl) obtained for the 88 selected compounds with the AM/MAC output.
TCMDC ID: Tres Cantos Medicine Discovery Center Identifier. Chemical structures and more information on
all compounds tested in these studies are available at reference 18 as TCMDC IDs (Tres Cantos Medicine
Discovery Center Identifiers).
TCMDC ID Cl TCMDC ID Cl TCMDC ID Cl
143101 A 143093 B 143407 D
143113 A 143094 B 125826 E
143122 A 143095 B 143077 E
143133 A 143211 C 143078 E
143557 A 143212 C 143621 E
143558 A 143213 C 143144 F
143570 A 143214 C 143168 F
143584 A 143216 C 143427 F
143639 A 143217 D 143139 H
143090 B 143218 D 143140 H
143091 B 143404 D 143141 H
143092 B 143406 D
https://doi.org/10.1371/journal.pntd.0005629.t002
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Effect of the serum type on pEC50
The effect of the serum used as medium supplement on compound potency was investigated
by comparing the pEC50 values at 96h obtained in the presence of horse serum, as described
in the present work, with those previously obtained with foetal bovine serum [18]. For the
whole group of 176 compounds, the pEC50s values were generally higher when determined in
FBS: 51% higher in FBS vs 20% higher in HS (AM/MAC output) and 49% higher in FBS vs
15% higher in HS (INF output). However, when the comparison was limited to the selected
hits, the really interesting compounds, this difference almost disappeared, with 35% of the
Fig 2. Complete set of chemical clusters obtained for the clustering exercise conducted with the 88 selected compounds
using the data of the AMMAC output and the 73 selected compounds using the data of the INF output.
https://doi.org/10.1371/journal.pntd.0005629.g002
Rate of action of “Leish box” hits
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0005629 May 25, 2017 8 / 16
pEC50 values higher in FBS and 27% higher in HS for AM/MAC output and 33% higher in
FBS and 26% higher in HS for INF output. These results are shown in Table 4.
Discussion
“Rate of action” assay to prioritise hits against L. donovani
Prioritisation of the most promising hits derived from screening campaigns at early stages of
the drug discovery process, usually at the “Hit Optimization” or “Hit to Lead” level, is a crucial
step to selectively accelerate the progression of “best in class” compounds. In fact, this step is
expected to increase the probabilities of success while reducing the time and efforts needed to
identify a candidate compound for development. Thus, the identification of new assays able to
prioritise those compounds presenting a favourable property amongst a set of promising hits
would represent a very important opportunity for drug discovery.
Table 3. Chemical clusters (Cl) obtained for the 73 selected compounds in the INF output. TCMDC ID:
Tres Cantos Medicine Discovery Center Identifier. Chemical structures and more information on all com-
pounds tested in these studies are available at reference 18 as TCMDC IDs (Tres Cantos Medicine Discovery
Center Identifiers).
TCMDC ID CI TCMDC ID CI TCMDC ID CI
143101 A 143093 B 143407 D
143113 A 143094 B 143144 F
143122 A 143095 B 143168 F
143133 A 143211 C 143427 F
143557 A 143212 C 143164 G
143558 A 143213 C 143166 G
143570 A 143214 C 143517 G
143584 A 143216 C 143139 H
143639 A 143217 D 143140 H
143090 B 143218 D 143141 H
143091 B 143404 D
143092 B 143406 D
https://doi.org/10.1371/journal.pntd.0005629.t003
Table 4. Effect of the serum used in the assay on the pEC50 values obtained. Second and third columns
represent data obtained for the AM/MAC output and for the INF output respectively. Data shown in the upper
four rows correspond to all the compounds tested (Leishmania donovani box) while the ones shown in the
lower four rows correspond to the selected sets of compounds (88 compounds for the AM/MAC output and 73
compounds for the INF output).
FBS vs HS (AM/MAC & INF) for initial compounds AM/MAC INF
176 cmpds 176 cmpds
pIC5096h FBS—pIC5096h HS > 0.1 89 (51%) 86 (49%)
pIC5096h FBS—pIC5096h HS (-0.1/0.1) 51 (29%) 63 (36%)
pIC5096h FBS—pIC5096h HS < 0.1 36 (20%) 27 (15%)
FBS vs HS (AM/MAC & INF) for selected compounds AM/MAC INF
88 cmpds 73cmpds
pIC5096h FBS—pIC5096h HS > 0.1 31 (35%) 24 (33%)
pIC5096h FBS—pIC5096h HS (-0.1/0.1) 33 (37%) 30 (41%)
pIC5096h FBS—pIC5096h HS < 0.1 24 (27%) 19 (26%)
https://doi.org/10.1371/journal.pntd.0005629.t004
Rate of action of “Leish box” hits
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GSK has recently published the results of three screening campaigns leading to the assembly
of three compound boxes active against the kinetoplastid parasites T. brucei, T. cruzi and L.
donovani [18]. Among the parameters used in drug discovery for the selection of hit com-
pounds, the rate of action is an important factor to take into account. This property is strongly
linked to the mode of action of each compound and deserves special attention at an early stage
of the drug discovery process. In the in vitro intra-macrophage assay here presented, ampho-
tericin B and miltefosine, two of the currently available drugs against visceral leishmaniasis,
showed different in vitro rate of action, with amphotericin B acting faster than miltefosine. For
this reason, in the present work, the rate of action of these drugs was used to analyse and clus-
ter compounds of the “L. donovani box”. The assay here presented was adapted from the in
vitro replicative assay recently described by our group [19]. The potency of each compound
was evaluated every 24 hours up to 96 hours and two different outputs, number of amastigotes
per macrophage (AM/MAC) and percentage of infected cells (INF), were used to calculate
pEC50s at each time point. As it has been previously demonstrated that the replication rate of
intracellular amastigotes infecting differentiated THP-1 lies around two days [19], 24-hour
time lapses appeared to be enough to study the evolution of pEC50 over time. Analysis of the
potency data for compounds of the “L. donovani box” led, after application of demanding
potency, selectivity and drug-like filters, to the identification of two hit sets that were pro-
gressed to biological and chemical clustering. The final aims were, on one hand, the prioritiza-
tion of fast-acting compounds within these compound sets and, on the other hand, the
validation of this assay by comparison of the results obtained with the biological and chemical
clusterings.
Biological clustering of selected compounds using AM/MAC and INF
outputs
The classification of compounds from the two outputs according to the rate of action was car-
ried out by comparing the pEC50 data at different time points for each compound with those
obtained with AB and MF. The criteria used for the classification were set up on the basis of
two experimental data: the difference of pEC50 values between 96h and 24h (Δ96h-24h), and the
difference of pEC50 values between 96h and 48h (Δ96h-48h). This exercise identified, for the
AM/MAC output, 64 (or 73%) compounds in group 1, 17 (or 19%) compounds in group 2 and
7 (or 8%) compounds in group 3. For the INF output, 49 (or 67%) compounds were in group
1, 13 (or 18%) compounds in group 2 and 11 (or 15%) compounds in group 3.
Most of the selected hits were characterized as fast-acting compounds probably due to the
high value of the hits included in the “L. donovani box”, that were selected after application of
very stringent potency and selectivity filters. However, the fact that still some slow acting com-
pounds were identified (group 3), demonstrates the power of this assay to identify this class of
compounds. In order to further prioritise these hits from group 1, standard filters could be
applied (higher pIC50 values, more favourable physico-chemical properties, chemical avail-
ability, etc. . .).
Comparison between biological clustering for AM/MAC and INF outputs
The pEC50 values at 96 hours showed a small but clear advantage for AM/MAC over INF
input. The population of the different groups showed similar results for both outputs: group 1,
was the most populated one (73% for AM/MAC and 67% for INF), followed by the intermedi-
ate group 2 (19% and 18%) and, finally, group 3 containing the slow-acting compounds (8%
and 15%).
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S8 Table shows results for biological compound clustering for AM/MAC and INF outputs.
Sixty-eight compounds were common to the two outputs. The vast majority of the studied
compounds (59 hits / 87%) showed “excellent” correlation, while it was assigned as “good” or
“poor” for 6 (9%) and 3 compounds (4%) respectively. This result seems to reflect the high
quality of the compounds included in the “L. donovani box”.
Chemical clustering of selected compounds using AM/MAC and INF
outputs
Once all compounds were classified through the biological clustering exercise, the validity of
the rate of action assay and the information extrapolated were determined comparing the bio-
logical results to the chemical clustering. The rate of action is a property directly linked to the
compound target or mechanism of action; thus, compounds acting through the same mecha-
nism of action are also expected to present similar rate of action and should be classified in the
same group by the assay here described. All compounds belonging to the same chemical class
are expected to act through the same mechanism of action and should, therefore, elicit a
response with a similar rate of action. In order to validate the biological results, we ran a chem-
ical clustering exercise using the two groups of compounds previously classified through the
biological clustering: the 88 high-quality hits identified within the AM/MAC output and the
73 identified within the INF output. In both cases, seven chemical scaffolds or clusters were
obtained, comprising 35 and 34 compounds respectively. The comparison of the two analysis
(Fig 3) showed that six of the seven chemical scaffolds independently identified by the two out-
puts were not only identical, but also included exactly the same 31 compounds, even though
the two groups contained different number of compounds, thus confirming the robustness of
the assay. In addition, the only different chemical scaffold for each output (clusters G and E)
was represented in the other output by either one or two compounds, an insufficient number
to be considered a chemical cluster, e.g. compound TCMDC-143164 in the AM/MAC output
and compounds TCMDC-125826 and TCMDC-143621 in the INF output. The reason why
less than half of the compounds (35 out of 88 for AM/MAC and 34 out of 73 for INF) were
included in a cluster resides in the remarkable chemical diversity represented within the “L
donovani box”. Thanks to the high-quality of the hits included in this box, seven chemical clus-
ters per output were identified and analysed, a number that, in our opinion, is enough to vali-
date the rate of action assay here described.
Comparison chemical and biological clustering for AM/MAC and INF
outputs
Even though the evaluation of the rate of action (biological clustering) and the determination
of the minimum chemical scaffold (chemical clustering) offer different information for every
compound, they are both linked to the compound mode of action. Thus, it is expected that
compounds belonging to the same chemical class will also be assigned to the same “rate of
action” group as defined in the present work. Comparison of the results shown in Fig 3 con-
firm this point, as compounds from five of the six chemical clusters identified for AM/MAC
and INF (clusters A-D, and F) presented all their members in the same group (group 1)
according to the biological clustering. In addition, the 2 compounds identified by the INF out-
put belonging to cluster E in AM/MAC, TCMDC-125826 and TCMDC-143621, were also clas-
sified in group 1 by the biological clustering. Clusters G in INF and H in AM/MAC and INF
deserve a special comment as the results suggest that these clusters are in the borderline of two
groups. The INF output shows, for cluster G, one compound (TCMDC-143166) in group 1
although very close to the limit 1/2, one compound (TCMDC-143517) in group 2 although
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very close to the limit 1/2 and one compound (TCMDC-143164) in group 2, suggesting the
cluster to present a rate of action close to the limit between groups 1 and 2. The only com-
pound of this series identified by AM/MAC, TCMDC-143164, was assigned to group 2, in
good agreement with this suggestion. Concerning cluster H, the analysis of the AM/MAC out-
put assigned the three compounds to group 2 while INF assigned two of them, TCMDC-
143139 and TCMDC-143140, to group 3 although very close to limit 2/3 too and one of them,
TCMDC-143141, to group 2 although very close to limit 2/3; it can be concluded that cluster
H presents a rate of action in the frontier between groups 2 and 3. In summary, an excellent
correlation was observed between the biological assay and the chemical clustering exercise as
well as between the two outputs used for those compounds clearly included in group 1 or, in
other words, the most promising compounds. For compounds belonging to groups 2 and 3,
the assay was also able to identify chemical clusters in the borderline of two groups. These
Fig 3. Comparison of the results obtained for the biological grouping and the chemistry clustering exercise using AM/MAC and INF
outputs for the selected compounds. Compound TCMDC IDs (Tres Cantos Medicine Discovery Center Identifiers): green (group 1), orange
(group 2) and red (group 3). Chemical structures for all compounds tested in these studies are available at reference 18 as TCMDC IDs (Tres
Cantos Medicine Discovery Center Identifiers).
https://doi.org/10.1371/journal.pntd.0005629.g003
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results clearly demonstrate the validity of this time-to-kill assay to prioritise and progress the
most promising hits obtained in an HTS campaign on the basis of the rate of action.
Conclusion
In conclusion, the assay here described allowed the grouping of the compounds of the “L.
donovani box” according to their rate of action, defined in comparison with standard drugs
amphotericin B and miltefosine. It was possible, in fact, to discriminate between compounds
faster, similar or slightly slower than fast-acting amphotericin B; faster, similar or slightly
slower than slow-acting miltefosine but slower than amphotericin B; and slower than both
drugs. Cross-comparison of the biological and chemical clustering for these compounds
revealed that molecules belonging to the same chemical series showed the same behaviour in
terms of rate of action. In particular, five chemical series were characterized as belonging to
group 1 when analysed using the AM/MAC or INF outputs. These series contain very promis-
ing compounds that deserve further studies by the scientific community. These data altogether
confirm this assay can provide very useful hints on the rate of action of new compounds and,
consequently, can be used for the prioritization of the most promising new chemical series
within a group of hits from screening. Likewise, it validates the tactics for the selection of hit
series based on joint chemical and biological clustering.
Supporting information
S1 Table. pEC50 values obtained for the 176 “L. donovani box” hits evaluated with the rate
of action assay using AM/MAC output at four time points (24, 48, 72 and 96 hours). The
pEC50 numbers represent the average of two assay runs. pEC50 = -log EC50 (M). TCMDC ID:
Tres Cantos Medicine Discovery Center Identifier. Chemical structures and more information
on all compounds tested in these studies are available at reference 18 as TCMDC IDs (Tres
Cantos Medicine Discovery Center Identifiers).
(PDF)
S2 Table. pEC50 values obtained for the 176 “L. donovani box” hits evaluated with the rate
of action assay using INF output at four time points (24, 48, 72 and 96 hours). The pEC50
numbers represent the average of two assay runs. pEC50 = -log EC50 (M). TCMDC ID: Tres
Cantos Medicine Discovery Center Identifier Chemical structures and more information on
all compounds tested in these studies are available at reference 18 as TCMDC IDs (Tres Cantos
Medicine Discovery Center Identifiers).
(PDF)
S3 Table. Z’ values calculated for the two outputs (AM/MAC and INF) at each time point.
(PDF)
S4 Table. pEC50 values obtained for the 88 “L. donovani box” selected hits evaluated with
the rate of action assay using AM/MAC output at four time points (24, 48, 72 and 96
hours). The pEC50 numbers represent the average of two assay runs. pEC50 = -log EC50 (M).
TCMDC ID: Tres Cantos Medicine Discovery Center Identifier. Chemical structures and
more information on all compounds tested in these studies are available at reference 18 as
TCMDC IDs (Tres Cantos Medicine Discovery Center Identifiers).
(PDF)
S5 Table. pEC50 values obtained for the 73 “L. donovani box” selected hits evaluated with
the rate of action assay using INF output at four time points (24, 48, 72 and 96 hours). The
pEC50 numbers represent the average of two assay runs. pEC50 = -log EC50 (M). TCMDC ID:
Rate of action of “Leish box” hits
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0005629 May 25, 2017 13 / 16
Tres Cantos Medicine Discovery Center Identifier. Chemical structures and more information
on all compounds tested in these studies are available at reference 18 as TCMDC IDs (Tres
Cantos Medicine Discovery Center Identifiers).
(PDF)
S6 Table. Rate of action classification of the 88 selected compounds with the AM/MAC
output and the reference drugs (R). Δ96h-24h = pEC5096h-pEC5024h; Δ96h-48h = pEC5096h-
pEC5048h; Gr = group assigned; Gr
 = alternative group. The alternative group reflects cases
where the pEC50 difference is very close to the limit value (± 0.2 for limit 1/2 and ± 0.15 for
limit 2/3). TCMDC ID: Tres Cantos Medicine Discovery Center Identifier. Chemical struc-
tures and more information on all compounds tested in these studies are available at reference
18 as TCMDC IDs (Tres Cantos Medicine Discovery Center Identifiers).
(PDF)
S7 Table. Rate of action classification of the 73 selected compounds with the INF output
and the reference drugs (R). Δ96h-24h = pEC5096h-pEC5024h; Δ96h-48h = pEC5096h-
pEC5048h; Gr = group assigned; Gr
 = alternative group. The alternative group reflects cases
where the pEC50 difference is very close to the limit value (± 0.2 for limit 1/2 and for limit 2/
3). TCMDC ID: Tres Cantos Medicine Discovery Center Identifier. Chemical structures and
more information on all compounds tested in these studies are available at reference 18 as
TCMDC IDs (Tres Cantos Medicine Discovery Center Identifiers).
(PDF)
S8 Table. Comparison of the results from the biological grouping exercise obtained for the
two selected sets of hits using the AM/MAC and INF outputs. Gr AM: group assigned using
the AM/MAC output. pEC50 96h: pEC50 value obtained at 96 hours using the corresponding
output (AM/MAC or INF). G2: alternative group assigned using the corresponding output
(AM/MAC or INF). Agree: type of agreement obtained for a compound when comparing
results from AM/MAC and INF outputs; it was defined as Excellent (E), Good (G), Poor (P) or
Not Applicable (NA) for those compounds for which there are not results for the two outputs.
pEC50 = -log EC50 (M). TCMDC ID: Tres Cantos Medicine Discovery Center Identifier.
Chemical structures and more information on all compounds tested in these studies are avail-
able at reference 18 as TCMDC IDs (Tres Cantos Medicine Discovery Center Identifiers).
(PDF)
Acknowledgments
From GSK, we thank Dolores Jimenez-Alfaro and SMTech Department for supplying com-
pounds pre-dispensed in microtiter plates and managing compound logistics. We are also
indebted to Manu de Rycker and scientists from Dundee University Drug Discovery Unit for
providing the L. donovani eGFP strain.
Author Contributions
Conceptualization: DT JC IP JM JMC.
Formal analysis: DT JC IP JM JMC.
Investigation: DT JC JMC.
Methodology: DT JC IP JM JMC.
Validation: DT JC.
Rate of action of “Leish box” hits
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0005629 May 25, 2017 14 / 16
Writing – original draft: DT JMC.
Writing – review & editing: JC IP JM.
References
1. Croft SL, Olliaro P. Leishmaniasis chemotherapy-challenges and opportunities. Clin Microbiol Infect.
2011; 17: 1478–1483. https://doi.org/10.1111/j.1469-0691.2011.03630.x PMID: 21933306
2. Sundar S, Chakravarty J. Liposomal amphotericin B and leishmaniasis: dose and response. J Glob
Infect Dis. 2010; 2: 159–166. https://doi.org/10.4103/0974-777X.62886 PMID: 20606972
3. Freitas-Junior LH, Chatelain E, Kim HA, Siqueira-Neto JL. Visceral leishmaniasis treatment: what do
we have, what do we need and how to deliver it? Int J Parasitol Drugs Drug Resist. 2012; 2: 11–19.
https://doi.org/10.1016/j.ijpddr.2012.01.003 PMID: 24533267
4. Sundar S, Olliaro PL. Miltefosine in the treatment of leishmaniasis: clinical evidence for informed clinical
risk management. Ther Clin Risk Manag. 2007; 3: 733–740. PMID: 18472998
5. Zheng W, Thorne N, McKew JC. Phenotypic screens as a renewed approach for drug discovery. Drug
Discov Today. 2013; 18: 1067–1073. https://doi.org/10.1016/j.drudis.2013.07.001 PMID: 23850704
6. Wyatt PG, Gilbert IH, Read KD, Fairlamb AH. Target validation: linking target and chemical properties
to desired product profile. Curr Top Med Chem. 2011; 11: 1275–1283. https://doi.org/10.2174/
156802611795429185 PMID: 21401506
7. Frearson JA, Wyatt PG, Gilbert IH, Fairlamb AH. Target assessment for antiparasitic drug discovery.
Trends Parasitol. 2007; 23: 589–595. https://doi.org/10.1016/j.pt.2007.08.019 PMID: 17962072
8. Gilbert IH. Drug discovery for neglected diseases: molecular target-based and phenotypic approaches.
J Med Chem. 2013; 56: 7719–7726. https://doi.org/10.1021/jm400362b PMID: 24015767
9. Castillo E, Dea-Ayuela MA, Bolas-Fernandez F, Rangel M, Gonzalez-Rosende ME. The kinetoplastid
chemotherapy revisited: current drugs, recent advances and future perspectives. Curr Med Chem.
2010; 17: 4027–4051. PMID: 20939823
10. Don R, Ioset JR. Screening strategies to identify new chemical diversity for drug development to treat
kinetoplastid infections. Parasitology. 2014; 141: 140–146. https://doi.org/10.1017/
S003118201300142X PMID: 23985066
11. Reguera RM, Calvo-Alvarez E, Alvarez-Velilla R, Balana-Fouce R. Target-based vs. phenotypic
screenings in Leishmania drug discovery: a marriage of convenience or a dialogue of the deaf? Int J
Parasitol Drugs Drug Resist. 2014; 4: 355–357. https://doi.org/10.1016/j.ijpddr.2014.05.001 PMID:
25516847
12. Schenone M, Dancik V, Wagner BK, Clemons PA. Target identification and mechanism of action in
chemical biology and drug discovery. Nat Chem Biol. 2013; 9: 232–240. https://doi.org/10.1038/
nchembio.1199 PMID: 23508189
13. Sanz LM, Crespo B, De-Cozar C, Ding XC, Llergo JL, Burrows JN, et al. P. falciparum in vitro killing
rates allow to discriminate between different antimalarial mode-of-action. PLoS One. 2012; 7: e30949.
https://doi.org/10.1371/journal.pone.0030949 PMID: 22383983
14. Bowling T, Mercer L, Don R, Jacobs R, Nare B. Application of a resazurin-based high-throughput
screening assay for the identification and progression of new treatments for human African trypanoso-
miasis. Int J Parasitol Drugs Drug Resist. 2012; 2: 262–270. https://doi.org/10.1016/j.ijpddr.2012.02.
002 PMID: 24533287
15. Le Manach C, Scheurer C, Sax S, Schleiferbock S, Cabrera DG, Younis Y, et al. Fast in vitro methods
to determine the speed of action and the stage-specificity of anti-malarials in Plasmodium falciparum.
Malar J. 2013; 12: 424. https://doi.org/10.1186/1475-2875-12-424 PMID: 24237770
16. Diaz R, Luengo-Arratta SA, Seixas JD, Amata E, Devine W, Cordon-Obras C, et al. Identification and
characterization of hundreds of potent and selective inhibitors of Trypanosoma brucei growth from a
kinase-targeted library screening campaign. PLoS Negl Trop Dis. 2014; 8: e3253. https://doi.org/10.
1371/journal.pntd.0003253 PMID: 25340575
17. De Rycker M, Thomas J, Riley J, Brough SJ, Miles TJ, Gray DW. Identification of trypanocidal activity
for known clinical compounds using a new Trypanosoma cruzi hit-discovery screening cascade. PLoS
Negl Trop Dis. 2016; 10: e0004584. https://doi.org/10.1371/journal.pntd.0004584 PMID: 27082760
18. Peña I, Manzano MP, Cantizani J, Kessler A, Alonso-Padilla J, Bardera AI, et al. New compound sets
identified from high throughput phenotypic screening against three kinetoplastid parasites: an open
resource. Sci Rep. 2015; 5: 8771. https://doi.org/10.1038/srep08771 PMID: 25740547
Rate of action of “Leish box” hits
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0005629 May 25, 2017 15 / 16
19. Tegazzini D, Diaz R, Aguilar F, Pena I, Presa JL, Yardley V, et al. A replicative in vitro assay for drug dis-
covery against Leishmania donovani. Antimicrob Agents Chemother. 2016; 60: 3524–3532. https://doi.
org/10.1128/AAC.01781-15 PMID: 27021313
20. Goyard S, Segawa H, Gordon J, Showalter M, Duncan R, Turco S J et al. An in vitro system for develop-
mental and genetic studies of Leishmania donovani phosphoglycans. Mol Biochem Parasitol. 2003; 130
(1): 31–42. PMID: 14550894
21. De Rycker M, Hallyburton I, Thomas J, Campbell L, Wyllie S, Joshi D, et al. Comparison of a high-
throughput high-content intracellular Leishmania donovani assay with an axenic amastigote assay.
Antimicrob Agents Chemother. 2013; 57: 2913–2922. https://doi.org/10.1128/AAC.02398-12 PMID:
23571538
Rate of action of “Leish box” hits
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0005629 May 25, 2017 16 / 16
